Printer Friendly

Teva Adds to Product Line, Expands R&D Capabilities.

SELLERSVILLE, Pa.--Teva Pharmaceuticals USA, one of the nation's leading generic drug manufacturers, is not content to rest on its laurels.

Formed in 1996 by the merger of Lemmon Co. and Biocraft Laboratories, Teva markets nearly 100 products, including almost half of the 50 most frequently dispensed generic medications, according to a spokesman for the company.

This year Teva has introduced a host of new products, including:

* Diclofenac Potassium tablets, 50 mg. The medication is AB rated and bloequivalent to Novartis Consumer Health Inc.'s Cataflam tablets.

* Pentoxifylline extended-release tablets, 400 mg. The product is AB rated and bioequivalent to Hoechst Marion Roussel Inc.'s Trental tablets, 400 mg.

* Clonazepam tablets in bottles of 500 and 1,000. The medication is AB rated and bloequivalent to Roche Laboratories' Klonopin tablets.

"Teva USA's Diclofenac Potassium tablets, Pentoxifylline extended-release tablets and Clonazepam tablets offer a cost-saving alternative to the brand product," notes vice president of sales and marketing Larry Rosenthal. "Our company is committed to developing and marketing quality products at competitive prices. We want customers to benefit from our expanding product line and focus on service."

In addition, the supplier recently expanded its research and development capabilities with the addition of a 10,000-square-foot analytical laboratory and office complex at its head- quarters here. The facility will be headed by John James, senior director of analytical research and development, and it is staffed by 26 scientists and technicians.

"Our new lab and office will greatly enhance our efficiency and help speed product development," remarks James.

The company also operates analytical research and development facilities in Waldwick and Fairfield, N.J.

"Teva USA has also recently completed two new pilot plants, one here in Sellersville and one in New Jersey," says Chris Pelloni, senior director of pharmaceutical research and development. "These small-scale manufacturing facilities are used to produce test batches of products in the early stages of development."

The plants help the company reduce costs, improve productivity and provide the added benefit of freeing full-scale production equipment to increase capacity, adds Pelloni.

Teva's parent company, Teva Pharmaceuticals Industries Ltd., develops, manufactures and markets pharmaceuticals for humans, bulk pharmaceutical chemicals, medical disposables, veterinary products and fermentation products.

The largest supplier of such products to Israel's public and private health care markets, the company has manufacturing facilities in Israel, eastern and western Europe and the United States, with nearly half its sales generated in the U.S.

COPYRIGHT 1998 Racher Press, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1998 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Chain Drug Review
Geographic Code:1USA
Date:Sep 28, 1998
Previous Article:Purepac Moves Drugs to Market Quickly.
Next Article:Ranbaxy Anticipates Needs of Marketplace.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters